Article Text

other Versions

PDF

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.
  1. Rogier M. Thurlings (r.m.thurlings{at}amc.uva.nl)
  1. Academic Medical Center/ University of Amsterdam, Netherlands
    1. Koen Vos (kvos{at}xs4all.nl)
    1. 1. Academic Medical Center/ University of Amsterdam 2. Jan van Breemen Institute, Amsterdam, Netherlands
      1. Carla A. Wijbrandts (c.a.wijbrandts{at}amc.uva.nl)
      1. Academic Medical Center/ University of Amsterdam, Netherlands
        1. Aeilko Zwinderman (a.h.zwinderman{at}amc.uva.nl)
        1. Academic Medical Center/ University of Amsterdam, Netherlands
          1. Danielle M Gerlag (d.m.gerlag{at}amc.uva.nl)
          1. Academic Medical Center/ University of Amsterdam, Netherlands
            1. Paul P Tak (p.p.tak{at}amc.uva.nl)
            1. Academic Medical Center/ University of Amsterdam, Netherlands

              Abstract

              Objective: To investigate the synovial tissue in rheumatoid arthritis (RA) patients treated with rituximab and to identify possible predictors of clinical response.

              Methods: Twenty-four RA patients underwent synovial biopsy before, 4 and 16 weeks after initiation of rituximab treatment (without peri-infusional corticosteroids to prevent bias). Immunohistochemical analysis was performed and stained sections were analyzed by digital image analysis. Linear regression analysis was used to identify predictors of clinical response.

              Results: The disease activity score (DAS28) was unaltered at 4 weeks, but significantly reduced at 16 and 24 weeks. Serum levels of IgM-rheumatoid factor (RF) decreased significantly at 24 weeks and anti-citrullinated peptide antibody (ACPA) levels at 36 weeks. Peripheral blood B cells were depleted at 4 weeks and started to return at 24 weeks. Synovial B cells were significantly decreased at 4 weeks, but were not completely depleted in all patients; there was a further reduction at 16 weeks in some patients. We found a significant decrease in macrophages at 4 weeks, which was more pronounced at 16 weeks. At that time point T cells were also significantly decreased. The reduction of plasma cells predicted clinical improvement at 24 weeks.

              Conclusions: The results support the view that B cells orchestrate local cellular infiltration. The kinetics of the serological as well as the tissue response in clinical responders are consistent with the notion that rituximab exerts its effects in part by an indirect effect on plasma cells associated with autoantibody production, which could help explain the delayed response after rituximab treatment.

              • biomarkers
              • predictive
              • rheumatoid arthritis
              • rituximab
              • synovial tissue

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.